Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Baxter's product, the Novum LVP, had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [3]. - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [3]. - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [3]. - The lawsuit suggests that there was an increased risk of customers being instructed to take Novum LVPs out of service and that Baxter would halt all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff [4]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [5].

Core Insights - Baxter International Inc. is a global healthcare company providing essential medical products, including devices, pharmaceuticals, and biotechnology, with a focus on Medical Products and Therapies [1] - The company faces competition from major players like Johnson & Johnson and Medtronic [1] Financial Performance - Baxter reported a third-quarter adjusted EPS of 69 cents, exceeding management's guidance of 58-62 cents and Wall Street's estimate of 60 cents [3] - The company's sales for the third quarter were $2.84 billion, reflecting a 5% year-over-year increase on a reported basis and a 2% increase on an operational basis, closely aligning with the consensus of $2.88 billion [4] - Despite the positive EPS results, Baxter lowered its 2025 guidance, which negatively impacted investor sentiment [3][6] Segment Performance - The Medical Products and Therapies segment reported sales of approximately $1.33 billion, showing a 1% decline on both a reported and operational basis, primarily due to reduced sales in the Infusion Therapies and Technologies division [5][6] - Strong global demand for other products partially offset the decline in the Medical Products and Therapies segment [5] Market Outlook - Stifel Nicolaus set a price target of $22 for Baxter, indicating a potential upside of approximately 14.73% from the current stock price of $19.18 [2] - Despite the optimistic price target, Baxter's stock has experienced a significant drop, reaching a 52-week low [2][6]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, about the December 15, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Baxter common stock during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3] - The deadline to move the Court to serve as lead plaintiff is December 15, 2025, with the lead plaintiff representing other class members [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has recovered hundreds of millions of dollars for investors [4] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4] Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients [5] - Specific issues included underinfusion, overinfusion, and complete non-delivery of fluids, with Baxter being aware of multiple malfunctions and injuries [5] - Baxter's inadequate remedial measures and the persistence of design flaws heightened the risk of halting sales and negatively impacted the company's statements regarding product safety and sales prospects [5]

Group 1 - Baxter International's stock experienced a significant decline of nearly 15% following a mixed third-quarter report that missed analyst profitability estimates [1] - Total sales for Baxter rose by 5% year over year to $2.84 billion, while net income not according to GAAP decreased by 14% to $355 million ($0.69 per share) [2] - The revenue figure fell short of the consensus analyst estimate of $2.88 billion, although the adjusted net profit exceeded the projection of $0.60 [3] Group 2 - Baxter's business segments showed varied performance, with Pharmaceuticals leading growth at 7% to $632 million, Healthcare Systems and Technologies increasing by 3% to $773 million, while Medical Products and Therapies declined by 1% to just under $1.33 billion [4] - The "other" category saw a significant increase, rising more than fivefold to $101 million [4] - Management's guidance for the full year anticipates sales growth of only 1% to 2% over the 2024 result, with adjusted net income forecasted at $2.35 to $2.40 per share, below the average analyst estimate of $2.44 [5]

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing false and misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly has systemic defects leading to serious patient risks [3][4]. Summary by Sections Allegations - The lawsuit claims that Baxter's Novum LVP product suffered from systemic defects causing malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but failed to adequately address them [3]. - The company's attempts to mitigate these issues through customer alerts were deemed insufficient, as design flaws persisted [3]. - There was an increased risk that customers would be advised to take existing Novum LVPs out of service, and Baxter might halt all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Class Action Details - The class period for the lawsuit is from February 23, 2022, to July 30, 2025 [3]. - Shareholders who purchased shares during this period are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for December 15, 2025 [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case's status [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [5].

Core Viewpoint - Baxter International Inc. has lowered its 2025 guidance again, leading to a decline in stock price, which hit a 52-week low [1][6] Financial Performance - The company reported a third-quarter adjusted EPS of 69 cents, exceeding management's guidance of 58-62 cents and Wall Street's estimate of 60 cents [2] - Sales for the third quarter reached $2.84 billion, reflecting a 5% year-over-year increase on a reported basis and a 2% increase on an operational basis, nearly aligning with the consensus of $2.88 billion [2] Segment Performance - Medical Products & Therapies sales were approximately $1.33 billion, showing a decline of 1% on both a reported and operational basis, attributed to reduced sales in the Infusion Therapies & Technologies division, though offset by strong demand for Advanced Surgery products [3] - Healthcare Systems & Technologies sales amounted to $773 million, up 3% on a reported basis and 2% on an operational basis, driven by demand for Care & Connectivity Solutions products [4] - Pharmaceutical sales totaled approximately $632 million, increasing by 7% on both a reported and operational basis, reflecting strength in Drug Compounding and Injectables & Anesthesia products [4] Guidance Adjustments - Baxter has revised its fiscal 2025 adjusted earnings guidance from $2.42-$2.52 per share to $2.35-$2.40 per share, compared to the consensus of $2.44 [5] - The company lowered its 2025 sales guidance from a range of $11.27 billion to $11.38 billion down to $11.06 billion to $11.17 billion, against the consensus of $11.31 billion [5] - Baxter anticipates sales growth of 4%-5% on a reported basis (down from 6%-7%) and 1%-2% on an operational basis (down from 3%-4%) [5] Future Expectations - For the fourth quarter, Baxter expects adjusted earnings of 52-57 cents, below the consensus of 70 cents, with projected sales growth of approximately 2% on a reported basis and a decline of about 2% on an operational basis [6] - At the time of publication, Baxter's shares were down 13.31% at $19.43, trading near its 52-week low of $21.33 [6]

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming December 15, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Baxter International, Inc. ("Baxter†or the "Company†) (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, inclusive (the "Class Period†). IF YOU SUFFERED A LOSS ON YOUR BAXTER INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CL. ...

Core Insights - Baxter International Inc. reported third-quarter 2025 adjusted earnings per share (EPS) of 69 cents, exceeding the Zacks Consensus Estimate of 60 cents by 15%, although the bottom line declined 14% from the previous year [1][6] - Revenues from continued operations totaled $2.84 billion, reflecting a 5% increase on a reported basis but missing the Zacks Consensus Estimate by 1% [2][6] - The company's shares fell 16.2% in pre-market trading due to lower-than-expected quarterly sales, with a year-to-date decline of 3.8% compared to the industry's growth of 6% [2] Revenue Details - Total revenues from continued operations were $2.84 billion, up 5% reported and 2% operationally, but missed expectations [2] - The Medical Products & Therapies segment generated $1.33 billion, down 1% on both reported and operational bases, primarily due to lower sales in Infusion Therapies & Technologies [4] - Infusion Therapies and Technologies sales were $1.02 billion, down 4% year over year, while Advanced Surgery sales rose 13% to $306 million [5][6] - Healthcare Systems and Technologies segment sales reached $773 million, up 3% year over year, driven by growth in Care & Connectivity Solutions [7] - Pharmaceuticals segment sales totaled $632 million, up 7% year over year, with strong performance in Drug Compounding and Injectables & Anesthesia [8][9] Margin Analysis - Adjusted gross profit was $1.12 billion, down 5.3% year over year, with an adjusted gross margin contraction of 430 basis points to 39.4% [10] - Selling, general and administrative expenses were $708 million, down 6% from the previous year, while research and development expenses totaled $118 million, down 9% [10] - Adjusted operating income from continuing operations was $423 million, up 8% year over year, with an adjusted operating margin improvement of 40 basis points to 14.9% [11] 2025 Guidance - For Q4 2025, Baxter anticipates sales growth of 2% reported and a decline of 2% operationally, with adjusted EPS expected in the range of 52-57 cents [12] - Full-year 2025 guidance for continuing operational sales growth is now 4-5% reported and 1-2% operationally, with adjusted EPS projected at $2.35-$2.40, down from previous guidance [13]

Core Insights - Baxter International reported $2.84 billion in revenue for Q3 2025, a 5% year-over-year increase, but EPS decreased to $0.69 from $0.80 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $2.87 billion, resulting in a surprise of -1.32%, while the EPS exceeded expectations by 15% [1] Financial Performance Metrics - U.S. Pharmaceuticals net sales were $177 million, slightly below the average estimate of $183.65 million, reflecting a -0.6% year-over-year change [4] - International Pharmaceuticals net sales reached $455 million, matching the average estimate and showing an 11% increase year-over-year [4] - Advanced Surgery net sales were $306 million, surpassing the average estimate of $289.33 million, with a year-over-year growth of 12.5% [4] - Other net sales skyrocketed to $101 million, significantly exceeding the estimated $91.79 million, marking a remarkable 494.1% increase year-over-year [4] - Infusion Therapies and Technologies net sales were $1.02 billion, below the estimated $1.08 billion, representing a -4.4% change compared to the previous year [4] Stock Performance - Baxter's shares have returned -4% over the past month, contrasting with the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. due to allegations of false and misleading statements regarding the safety and efficacy of its Novum LVP product, which has led to significant investor losses [3][5][6]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Baxter [3]. - Investors who purchased Baxter securities between February 23, 2022, and July 30, 2025, are encouraged to discuss their legal rights with the firm [1][3]. Group 2: Allegations Against Baxter - The complaint alleges that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which caused malfunctions and posed serious risks to patients [5]. - Specific issues cited include underinfusion, overinfusion, and complete non-delivery of fluids, along with inadequate remedial measures taken by Baxter [5]. - The true extent of the issues was revealed on July 31, 2025, when Baxter announced a voluntary pause in shipments and installations of the Novum LVP, resulting in a 22.4% drop in stock price [6]. Group 3: Investor Participation - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members [7]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [7]. Group 4: Contact Information - Faruqi & Faruqi encourages anyone with information regarding Baxter's conduct, including whistleblowers and former employees, to contact the firm [8].